Prostate Oncology

前列腺肿瘤学

• 批准号: 8300276
• 负责人: MAX S. WICHA
• 金额: $ 36.67万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-06-01 至 2017-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8300276
• 关键词: Age; Aging; Apoptotic; Area; Biological Markers; Biology; Cancer Center; Cancer Center Support Grant; Cancer Family; Cancer Patient; Cancer Therapy Evaluation Program; Candidate Disease Gene; Caring; Castration; Cell Line; Chromosome Mapping; Clinic; Clinical; Clinical Research; Clinical Trials; Collaborations; Commit; Correlative Study; DNA; DNA Methyltransferase; DNA Modification Methylases; DNA Tumor Viruses; Data; Department of Defense; Detection; Development; Diagnosis; Disease; Disease Progression; E2F1 gene; EZH2 gene; Early Diagnosis; Environment; Epidemiology; Epigenetic Process; Epithelial; Etiology; Event; Family; Funding; Gene Expression; Genes; Genetic; Genetic Transcription; Genotype; Goals; Grant; Growth; Histone Deacetylase; Human; IL6 gene; Individual; Infection; Inherited; Integrins; Interleukin-6; Investigation; Laboratories; Ligands; Link; Malignant - descriptor; Malignant Bone Neoplasm; Malignant Neoplasms; Malignant neoplasm of prostate; Medical; Medical Oncologist; Metalloproteases; Metastatic Neoplasm to the Bone; Mission; Molecular; Morbidity - disease rate; National Institute of Diabetes and Digestive and Kidney Diseases; Neoplasm Metastasis; Oncogenes; Outcome; Pathway interactions; Patients; Polyomavirus; Predisposition; Prevention; Prostate; Prostate Cancer therapy; Prostatic Neoplasms; Proteins; Proteomics; Publications; Publishing; Quality of life; Radiation Oncology; Radiosurgery; Research; Research Personnel; Research Support; Research Training; Resistance; Resources; Robin bird; Role; Sampling; Scanning; Schools; Scientist; Seeds; Seminal; Serum; Site; Solutions; Southwest Oncology Group; Structure of base of prostate; Surveys; System; Technology; Testing; Therapeutic Intervention; Therapy Clinical Trials; Training; Transformed Cell Line; Translating; Translational Research; Treatment-Related Cancer; Tumor Suppressor Genes; United States National Institutes of Health; University of Michigan Comprehensive Cancer Center; Urologic Cancer; Urologic Oncology; Urologist; Urology; Vascular Endothelial Growth Factor Receptor-2; Vorinostat; Wood material; angiogenesis; base; bone; cancer genetics; clinical practice; clinically relevant; cohort; disease diagnosis; early onset; exome; genetic analysis; genome wide association study; genome-wide linkage; improved; inhibitor/antagonist; meetings; member; men; mortality; multidisciplinary; new technology; novel; oncology; oncology program; outcome forecast; programs; prospective; prostate cancer prevention; receptor; standard of care; survivorship; therapy development; tool; tumor; tumor growth; tumor progression

The Prostate Oncology Program is an interdisciplinary group of 34 laboratory, translational and clinical researchers from 11 departments and four schools with over $13 million in annual direct research support including nearly $4 million from the NCI. The Prostate Oncology Program, formerly the Urologic Oncology Program, was renamed during this grant period to reflect Its primary mission and critical mass of strength In translating basic and clinical discoveries in prostate cancer into effective medical solutions. The program includes a Prostate SPORE (recently renewed), a PO1 on the Biology of Prostate Cancer Bone Metastasis (recently renewed), a recently renewed Department of Defense funded Prostate Cancer Clinical trials Consortium site (DOD-PCCTC), a prostate-focused Early Disease Research Network (EDRN) site (new this period) and a NIDDK training grant In Clinical and Translational Research Training in Urology (T32). Over this grant period the 34 program members published 563 publications of which 27,9% are intraprogrammatic and 31.3% are Inter-programmatic collaborations. The Program is committed to creating and sustaining a multidisciplinary environment for basic and clinical researchers studying prostate cancer. The scientific aims of the Prostate Oncology Programs are 1) to investigate the genetic and epigenetic events that contribute to malignant transformation in prostate cancer, 2) to characterize aberrations in the tumor microenvironment that facilitate the growth or metastasis of prostate cancer, 3) to translate basic scientific discoveries to develop new biomarkers and therapies in urologic cancers, and 4) to evaluate clinical outcomes with the purpose of guiding therapy development while reducing cancer-related mortality as well as cancer and therapy-associated morbidity. Among the most high Impact research conducted during this grant period were the seminal findings related to the discovery of TMPRSS-ETS fusions in prostate cancer by program members. The objective of the Prostate Oncology Program Is to understand the biology of prostate cancer and to use this information to develop new tools for the detection, diagnosis, prevention, and treatment of prostate cancer.

前列腺肿瘤学计划是一个跨学科小组，由来自11个部门和4所学校的34名实验室，翻译和临床研究人员组成，每年直接研究支持超过1300万美元，其中包括来自NCI的近400万美元。前列腺肿瘤学项目，前身为泌尿肿瘤学项目，在此资助期间更名，以反映其主要使命和关键质量的力量，将前列腺癌的基础和临床发现转化为有效的医疗解决方案。该计划包括前列腺孢子（最近更新），前列腺癌骨转移生物学的PO 1（最近更新），最近更新的国防部资助的前列腺癌临床试验联盟网站（DOD-PCCTC），以前列腺为重点的早期疾病研究网络（EDRN）网站（本期新）和NIDDK培训补助金在泌尿外科临床和转化研究培训（T32）。在此期间，34个项目成员发表了563篇出版物，其中27.9%是项目内合作，31.3%是项目间合作。该计划致力于为研究前列腺癌的基础和临床研究人员创造和维持多学科环境。前列腺肿瘤学项目的科学目标是：1）研究导致前列腺癌恶性转化的遗传和表观遗传事件，2）表征促进前列腺癌生长或转移的肿瘤微环境中的畸变，3）将基本科学发现转化为泌尿系统癌症的新生物标志物和疗法，和4）评估临床结果，目的是指导治疗开发，同时降低癌症相关死亡率以及癌症和治疗相关发病率。在此资助期间进行的影响最大的研究是与项目成员发现前列腺癌中TMPRSS-ETS融合相关的开创性发现。前列腺肿瘤学项目的目标是了解前列腺癌的生物学，并利用这些信息开发用于检测，诊断，预防和治疗前列腺癌的新工具。